ArticlePloS one2024
Site-specific prediction of O-GlcNAc modification in proteins using evolutionary scale model.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein glycosylation, a vital post-translational modification, is pivotal in various biological processes and disease pathogenesis. Computational approaches, including protein language models and machine learning algorithms, have emerged as valuable tools for predicting O-GlcNAc sites, reducing experimental costs, and enhancing efficiency. However, the literature has not reported the prediction of O-GlcNAc sites through the evolutionary scale model (ESM). Therefore, this study employed the ESM-2 model for O-GlcNAc site prediction in humans. Approximately 1100 O-linked glycoprotein sequences retrieved from the O-GlcNAc database were utilized for model training. The ESM-2 model exhibited consistent improvement over epochs, achieving an accuracy of 78.30%, recall of 78.30%, precision of 61.31%, and F1-score of 68.74%. However, compared to the traditional models which show an overfitting on the same data up to 99%, ESM-2 model outperforms in terms of optimal training and testing predictions. These findings underscore the effectiveness of the ESM-2 model in accurately predicting O-GlcNAc sites within human proteins. Accurately predicting O-GlcNAc sites within human proteins can significantly advance glycoproteomic research by enhancing our understanding of protein function and disease mechanisms, aiding in developing targeted therapies, and facilitating biomarker discovery for improved diagnosis and treatment. Furthermore, future studies should focus on more diverse data types, longer protein sequence lengths, and higher computational resources to evaluate various parameters. Accurate prediction of O-GlcNAc sites might enhance the investigation of the site-specific functions of proteins in physiology and diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.